Scientists discover minuscule silver particles to kill brain-eating amoeba

Since 1962, only four of 143 known victims in the United States have survived

brain
Emily Baumgaertner | NYT
Last Updated : Feb 16 2019 | 11:27 PM IST
The brain-eating monsters are real enough — they lurk in freshwater ponds in much of the United States. Now scientists may have discovered a new way to kill them.
 
Minuscule silver particles coated with anti-seizure drugs one day may be adapted to halt Naegleria fowleri, an exceptionally lethal microbe that invades through the sinuses and feeds on human brain tissue.

The research, published in the journal Chemical Neuroscience, showed that repurposing seizure medicines and binding them to silver might kill the amoebae while sparing human cells. Scientists hope the findings will lay an early foundation for a quick cure. “Here is a nasty, often devastating infection that we don’t have great treatments for,” said Edward T. Ryan, the director of the global infectious diseases division of Massachusetts General Hospital, who was not involved in the research. “This work is clearly in the early stages, but it’s an interesting take.” Infections with brain-eating amoebae are rare but almost always deadly. 

Since 1962, only four of 143 known victims in the United States have survived, according to the Centers for Disease Control and Prevention. More than half of all cases have occurred in Texas and Florida, where the microscopic organisms thrive in warm pond water. “The classic case is a 10-year-old boy who goes swimming in the South in the summer and starts to get a headache a few days later,” Ryan said. The amoebae’s feeding causes meningoencephalitis — or swelling of the brain and nearby tissues — and is often misdiagnosed. “When it comes to treatment, doctors often end up throwing in the kitchen sink,” he added. Patients typically are given antimicrobial drugs in extremely high doses in order to break through the body’s protective blood-brain barrier. Many suffer severe side effects.

“The biggest challenge is finding a drug that can actually reach the right region of the brain,” said Ayaz Anwar, a researcher at Sunway University in Malaysia, who led the new study.
©2019TheNewYorkTimesNewsService

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story